UBS Group’s Anixa Biosciences ANIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.64M | Buy |
585,430
+33,793
| +6% | +$94K | ﹤0.01% | 5293 |
|
|
2026
Q1 | $1.42M | Buy |
551,637
+92,564
| +20% | +$274K | ﹤0.01% | 5268 |
|
|
2025
Q4 | $1.43M | Sell |
459,073
-15,407
| -3% | -$63.1K | ﹤0.01% | 5262 |
|
|
2025
Q3 | $1.57M | Sell |
474,480
-30,810
| -6% | -$97.5K | ﹤0.01% | 5192 |
|
|
2025
Q2 | $1.67M | Sell |
505,290
-18,872
| -4% | -$53.9K | ﹤0.01% | 4996 |
|
|
2025
Q1 | $1.5M | Sell |
524,162
-9,962
| -2% | -$28.5K | ﹤0.01% | 4941 |
|
|
2024
Q4 | $1.24M | Buy |
534,124
+4,726
| +0.9% | +$14.7K | ﹤0.01% | 5142 |
|
|
2024
Q3 | $1.67M | Sell |
529,398
-1,142
| -0.2% | -$3.51K | ﹤0.01% | 4183 |
|
|
2024
Q2 | $1.17M | Sell |
530,540
-5,767
| -1% | -$16.4K | ﹤0.01% | 4264 |
|
|
2024
Q1 | $1.67M | Sell |
536,307
-44,271
| -8% | -$177K | ﹤0.01% | 4115 |
|
|
2023
Q4 | $2.25M | Sell |
580,578
-23,861
| -4% | -$80.5K | ﹤0.01% | 3683 |
|
|
2023
Q3 | $1.98M | Sell |
604,439
-29,840
| -5% | -$104K | ﹤0.01% | 3445 |
|
|
2023
Q2 | $2.03M | Sell |
634,279
-4,717
| -0.7% | -$18.2K | ﹤0.01% | 3508 |
|
|
2023
Q1 | $2.75M | Buy |
638,996
+16,452
| +3% | +$72K | ﹤0.01% | 3088 |
|
|
2022
Q4 | $2.65M | Buy |
622,544
+853
| +0.1% | +$4.1K | ﹤0.01% | 3113 |
|
|
2022
Q3 | $3.06M | Buy |
621,691
+16,285
| +3% | +$66K | ﹤0.01% | 2788 |
|
|
2022
Q2 | $1.85M | Buy |
605,406
+6,965
| +1% | +$22K | ﹤0.01% | 3219 |
|
|
2022
Q1 | $1.64M | Buy |
598,441
+2,642
| +0.4% | +$7.75K | ﹤0.01% | 3633 |
|
|
2021
Q4 | $1.77M | Buy |
595,799
+13,391
| +2% | +$54.1K | ﹤0.01% | 3837 |
|
|
2021
Q3 | $2.78M | Sell |
582,408
-104,894
| -15% | -$473K | ﹤0.01% | 3277 |
|
|
2021
Q2 | $2.67M | Buy |
687,302
+99,821
| +17% | +$425K | ﹤0.01% | 3300 |
|
|
2021
Q1 | $2.75M | Sell |
587,481
-30,762
| -5% | -$147K | ﹤0.01% | 3225 |
|
|
2020
Q4 | $1.9M | Buy |
618,243
+90,200
| +17% | +$227K | ﹤0.01% | 3454 |
|
|
2020
Q3 | $1.28M | Buy |
528,043
+7,250
| +1% | +$18.7K | ﹤0.01% | 3461 |
|
|
2020
Q2 | $1.59M | Buy |
520,793
+179,148
| +52% | +$371K | ﹤0.01% | 3094 |
|
|
2020
Q1 | $543K | Buy |
341,645
+50,585
| +17% | +$148K | ﹤0.01% | 3888 |
|
|
2019
Q4 | $955K | Buy |
291,060
+30,017
| +11% | +$110K | ﹤0.01% | 4259 |
|
|
2019
Q3 | $1.04M | Buy |
261,043
+27,300
| +12% | +$114K | ﹤0.01% | 3932 |
|
|
2019
Q2 | $848K | Buy |
233,743
+27,000
| +13% | +$114K | ﹤0.01% | 3881 |
|
|
2019
Q1 | $934K | Buy |
206,743
+38,400
| +23% | +$183K | ﹤0.01% | 3634 |
|
|
2018
Q4 | $663K | Buy |
168,343
+29,550
| +21% | +$127K | ﹤0.01% | 4042 |
|
|
2018
Q3 | $644K | Buy |
138,793
+93,550
| +207% | +$352K | ﹤0.01% | 4219 |
|
|
2018
Q2 | $137K | Buy |
45,243
+38,864
| +609% | +$144K | ﹤0.01% | 5219 |
|
|
2018
Q1 | $24K | Sell |
6,379
-744
| -10% | -$2.86K | ﹤0.01% | 6271 |
|
|
2017
Q4 | $16K | Sell |
7,123
-817
| -10% | -$2.12K | ﹤0.01% | 6713 |
|
|
2017
Q3 | $21K | Buy |
7,940
+513
| +7% | +$564 | ﹤0.01% | 6400 |
|
|
2017
Q2 | $9K | Buy |
7,427
+4,112
| +124% | +$5.7K | ﹤0.01% | 6828 |
|
|
2017
Q1 | $10K | Sell |
3,315
-745
| -18% | -$3.2K | ﹤0.01% | 6595 |
|
|
2016
Q4 | $22K | Sell |
4,060
-1,103
| -21% | -$6.13K | ﹤0.01% | 6450 |
|
|
2016
Q3 | $20K | Buy |
5,163
+2,934
| +132% | +$9.78K | ﹤0.01% | 6280 |
|
|
2016
Q2 | $7K | Sell |
2,229
-2,941
| -57% | -$8.96K | ﹤0.01% | 6956 |
|
|
2016
Q1 | $16K | Sell |
5,170
-3,298
| -39% | -$9.46K | ﹤0.01% | 6348 |
|
|
2015
Q4 | $26K | Buy |
8,468
+3,572
| +73% | +$12.5K | ﹤0.01% | 6456 |
|
|
2015
Q3 | $24K | Buy |
+4,896
| New | +$22.8K | ﹤0.01% | 6513 |
|
Other funds holding ANIX
LNWTC
DADC
GCP
UBS Group's ANIX Position: Q2 2026 in Review
UBS Group increased its Anixa Biosciences (ANIX) stake by 6.1% in Q2 2026, buying an estimated $94K and bringing the position to 585,430 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5293.
UBS Group first reported a position in ANIX in Q3 2015 and has held it in 44 quarters since. The position peaked at $3.06M in Q3 2022. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.
- UBS Group held 585,430 shares of Anixa Biosciences worth $1.64M as of Q2 2026.
- UBS Group bought 33,793 Anixa Biosciences shares in Q2 2026, an estimated $94K.
- Anixa Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5293 holding.
- UBS Group first reported a position in Anixa Biosciences in Q3 2015 and has held it in 44 quarters since.
- UBS Group's Anixa Biosciences position peaked at $3.06M in Q3 2022.
- 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.